Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382108 | 0.93 | ACE (0.41) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2233402 | 0.93 | ACE (0.40) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2236787 | 0.92 | MEN1 (0.47) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2238532 | 0.92 | MEN1 (0.47) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2234466 | 0.92 | MEN1 (0.47) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2235328 | 0.90 | ACE (0.39) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2233958 | 0.87 | MEN1 (0.45) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2233645 | 0.86 | ACE (0.38) | ACEDRD2TDP1MEN1GAA | |
| SCHEMBL2232600 | 0.85 | SIRT5 (0.36) | NR1I3SIRT5CTSLCTSBCTSK | |
| SCHEMBL12255869 | 0.85 | GRIN1 (0.37) | ACEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | ACE 473/4885DRD2 3857/4885TDP1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.